Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881107083816v1
22/3/262    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Potvin, S.
Right arrow Articles by Stip, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Potvin, S.
Right arrow Articles by Stip, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on May 1, 2008
Journal of Psychopharmacology, Vol. 22, No. 3, 262-269 (2008)
DOI: 10.1177/0269881107083816

Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy

Stéphane Potvin

Fernand-Seguin Research Center, Louis-H Lafontaine Hospital and Biomedical Sciences Program, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada

Édouard Kouassi

Department of Medicine, Faculty of Medicine, University of Montreal and Maisonneuve-Rosemont Hospital Research Center, Montreal, Quebec, Canada

Olivier Lipp

Fernand-Seguin Research Center, Louis-H Lafontaine Hospital and Department of Psychiatry, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada

Roch-Hugo Bouchard

Centre de Recherche, Université Laval Robert-Giffard, Quebec, Canada

Marc-André Roy

Centre de Recherche, Université Laval Robert-Giffard, Quebec, Canada

Marie-France Demers

Centre de Recherche, Université Laval Robert-Giffard, Quebec, Canada

Alain Gendron

AstraZeneca Pharmaceuticals, Montreal, Quebec, Canada

Giuseppe Astarita

Departments of Pharmacology and Biological Chemistry, University of California, Irvine, CA, USA

Daniele Piomelli

Departments of Pharmacology and Biological Chemistry, University of California, Irvine, CA, USA

Emmanuel Stip

Fernand-Seguin Research Center, Louis-H Lafontaine Hospital and Department of Psychiatry, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada, emmanuel.stip{at}umontreal.ca

Disturbances in the endogenous cannabinoid (ECB) system in schizophrenia may contribute to their enhanced sensitivity to psychoactive substances, and the beneficial effects of second-generation antipsychotics for substance abuse in schizophrenia may involve modulatory effects on ECB. To verify these two assumptions, 29 patients (24 completers) with schizophrenia and substance use disorders (SUD) were treated with quetiapine for 12 weeks, and peripheral ECB levels were measured, using high-performance liquid chromatography/mass spectrometry, in patients (weeks 0, 6 and 12) and 17 healthy volunteers. Baseline anandamide levels were significantly higher in patients, relative to controls. This result is consistent with studies describing ECB dysfunctions in schizophrenia. SUD parameters improved during treatment, but no changes in ECB occurred over time. Improvements in substance abuse were probably not mediated by modulatory effects of quetiapine on ECB. Lastly, baseline anandamide predicted endpoint SUD scores (alcohol/ cannabis). Anandamide is a potential target for medications aimed at relieving SUD in schizophrenia.

Key Words: schizophrenia • substance use disorders • cannabis • endogenous cannabinoids • anandamide • quetiapine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?